Observational studyJournal of neuroendocrinology2025
Tumor-infiltrating immune cells predict the response to somatostatin receptor ligands only in somatotropinomas naïve to medical therapy.
Observational study in Journal of neuroendocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Can acromegaly be controlled in all cases?Journal of neuroendocrinology · 2026Review
- External validation of the PANOMEN-3 classification for predicting 1-year surgical remission in pituitary adenoma.Pituitary · 2026Article
- Tumor-infiltrating immune cells predict the response to somatostatin receptor ligands only in somatotropinomas naïve to medical therapy.Journal of neuroendocrinology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Tumor-infiltrating immune cells (TICs) are important components of the tumor microenvironment (TME). They regulate somatotroph adenoma treatment responses to therapy with somatostatin receptor ligands (SRLs), mediated by soluble factors and cytokines. In this study, we assessed the effect of SRLs treatment on TICs. A retrospective and observational study was performed on acromegaly patients to compare the number of TICs in 75 patients naïve to SRL before surgery and in 33 patients treated with SRL for at least 6 months before surgery. In SRLs-naive patients at surgery, the CD68+/CD8+ ratio was higher in invasive tumors (4.9, IQR: 14, p = .028) than in non-invasive tumors (4.3, IQR: 4.2) as well as in patients not responsive to post-surgical/adjuvant treatment with SRLs (7.5, IQR: 13, p = .006) than those responsive to treatment (3.4, IQR: 3.2). In patients treated with SRLs before surgery, the number of CD68+ macrophages and the ratio CD68+/CD8+ were lower in patients non-responsive to post-surgery/adjuvant SRL treatment (CD68+: 48/HPFs, IQR: 22.9, p = .005; CD68+/CD8+: 2.0, IQR: 3.6, p = .05) than in responsive patients (CD68+: 80/HFPs, IQR: 51, CD68+/CD8+: 5, IQR: 5.6). Higher CD68+/CD8+ ratio was an independent risk factor for post-surgery SRL treatment resistance, only in patients naïve to SRLs at surgery (OR: 4.3, 95% IC: 1.4-12.9, p = .006). Our results indicate a presurgical SRL therapy interplay with TICs in somatotroph adenomas and show that the CD68+/CD8+ ratio is a biomarker for treatment resistance in SRL-naïve patients. CLINICAL
trial registrationThe Clinical Trial Registration number is 5116.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.